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Introduction. Kidney disease is a worldwide health and economic burden, with rising prevalence. The search for biomarkers for
earlier and more effective disease screening and monitoring is needed. Oxidative stress has been linked to both, acute kidney
injury (AKI) and chronic kidney disease (CKD). The aim of our study was to investigate whether the concentrations of systemic
markers of oxidative stress and antioxidant status are affected by AKI and CKD, and to identify potential biomarkers. Methods.
In adult male Wistar rats, AKI was induced by bilateral nephrectomy, and CKD was induced by 5/6 nephrectomy. Blood was
collected 48 hours after surgery in AKI and 6 months after surgery in CKD. Advanced oxidation protein products (AOPP),
thiobarbituric acid reactive substances (TBARS), advanced glycation end products (AGEs), fructosamine, total antioxidant
capacity (TAC), and ferric reducing antioxidant power (FRAP) were measured. Results. Impaired renal function was confirmed
by high concentrations of plasma creatinine and urea in AKI and CKD animals. AOPP and fructosamine were higher by 100%
and 54% in AKI, respectively, and by 100% and 199% in CKD, respectively, when compared to corresponding control groups.
Similarly, there was approximately a twofold increase in AGEs (by 92%) and TAC (by 102%) during AKI. In CKD,
concentrations of FRAP, as an antioxidative status marker, were doubled (by 107%) when compared to the control group, but
concentration of TAC, another marker of antioxidative status, did not differ between the groups. Conclusions. AKI and CKD led
to increased systemic oxidative stress. AOPP and fructosamine could be considered potential biomarkers for both, acute and
chronic kidney damage. On the other hand, AGEs, TAC, and FRAP seem to be disease specific, which could help to differentiate
between acute and chronic kidney injuries. However, this needs further validation in clinical studies.
1. Introduction
Kidney disease can be classified into two types: acute kidney
injury (AKI) and chronic kidney disease (CKD). The global
prevalence of both forms of kidney disease is rising continu-
ously, in part due to the aging population and in part due to a
global increase in the prevalence of hypertension and diabe-
tes. AKI is characterized by a sudden loss of kidney function
within 7 days. CKD develops due to a structural or functional
kidney irregularity that persists for at least 3 months. Both
AKI and CKD result in the accumulation of toxic end prod-
ucts of nitrogen metabolism and creatinine in the blood
[1–3]. Research is focused on the search for more effective
and less costly therapies of AKI and end-stage CKD. More
importantly, the search for screening methods of earlier detec-
tion and more effective disease monitoring is ongoing [4].
Oxidative stress is a state of imbalance between the
generation of prooxidants and the number of antioxidants
present in favor of prooxidants. Free radicals and nonradical
oxidants alter biomolecules, mainly lipids, proteins, and
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nucleic acids, ultimately leading to cell death. Mitochondria
provide the main energy source for cells. In the kidney, renal
tubular cells are especially rich in mitochondria, because the
reabsorption of solutes is highly energy demanding. Renal
tubules are particularly vulnerable to oxidative stress and
damage, since mitochondria are one of the main sites of
intracellular free radical production via the respiratory
chain and NADPH oxidases [5–7]. Increased production of
prooxidants is involved in many pathological pathways of
AKI and CKD [8].
In CKD, impaired mitochondrial function and enhanced
mitochondrial reactive oxygen species (ROS) has been pro-
posed as one of the causes of elevated oxidative stress [9].
Increased production of mitochondrial ROS was shown in
the kidneys of diabetic mice [10–12]. In AKI, oxidative
damage and decreased antioxidant status can develop in the
renal tissue due to ischemia and toxic damage [13–15]. Also,
oxidative stress is a key factor in the pathogenesis of
rhabdomyolysis-induced myoglobinuric AKI [16]. Another
source of oxidative stress in later stages of CKD may be the
presence of uremic toxins and dysregulated metabolic waste
disposal [17–23]. In patients with CKD, uremia-specific risk
factors, including volume expansion, chronic inflammation,
anemia, or a microinflammatory state, are associated with
systemic oxidative stress that in turn could cause inflamma-
tion and further tissue damage [6]. Thus, oxidative stress
can affect the progression of renal disease as well in a bidirec-
tional manner. It can aggravate inflammation, contribute to
the development of fibrosis, via enhanced inflammation
and trigger signaling pathways leading to renal tubular cell
death. Fibrosis and inflammation might increase further for-
mation of ROS [24]. According to the above-mentioned
studies, it has been shown that oxidative stress is strongly
associated with AKI and CKD and their complications. How-
ever, it is still questionable whether an elevated production of
prooxidants is the only reason of oxidative stress. Uremic
toxins bolster inflammation along with oxidative stress by
priming polymorphonuclear leukocytes and triggering an
innate immune response. Uric acid synthesis can further
promote oxidative stress through the activity of xanthine
oxidoreductase. On the other hand, the uric acid itself
can act as an antioxidant [25–27].
Thus, oxidative stress and antioxidant status markers
need to be analyzed in detail. Oxidative status is commonly
assessed in the plasma by measuring the concentrations of
damaged biomolecules by free radicals and other oxidants.
Lipid peroxidation is routinely measured by the thiobarbitu-
ric acid-reacting substance (TBARS) method [28]. For the
evaluation of protein oxidation, advanced oxidation protein
products (AOPP) are assessed [29]. Advanced glycation end
products (AGEs) along with fructosamine are formed as
late-stage products of nonenzymatic glycation of amino
groups of proteins by the carbonyl compound of sugars,
and they are used as markers of carbonyl stress [30]. Total
antioxidant capacity (TAC) and ferric reducing antioxidant
power (FRAP) are commonly used methods for the assess-
ment of the antioxidant status [31, 32].
To our knowledge, only very few studies describing oxi-
dative stress and antioxidant status markers in detail in both
AKI and CKD have been published. The most recent one
suggests that salivary AOPP could be a suitable marker for
the detection of CKD in children with 92% sensitivity and
specificity [33]. Since AOPP are nonspecific, a panel of oxida-
tive stress markers would be more helpful in the detection of
CKD or AKI. Therefore, the main goal of this study was to
experimentally determine the effect of acute kidney injury
and chronic kidney disease on the systemic oxidative status.
In addition, AKI and CKDwere analyzed in parallel to search
for possible differences between the two conditions, which
might prove useful in the differentiation between progressive
CKD and AKI as a complication of CKD or alone.
2. Methods
2.1. Animals. Twelve-week-old adult male Wistar rats were
used in this experiment (n = 40 in total, weighing 294 ± 79
grams, Anlab, Prague, Czech Republic). Rats were housed
in standard cages with wood chip bedding, in a room with
an ambient temperature of 22 ± 1°C, 40-50% humidity, and
a 12/12-hour light/dark cycle. All rats had ad libitum access
to standard rodent chow and tap water throughout the
experiment. This study was approved by the Ethics Com-
mittee of the Institute of Pathophysiology, Comenius
University, and was carried out according to relevant
national legislation.
2.2. Modeling of Acute Kidney Injury. Bilateral nephrectomy
was performed to model AKI. Rats were divided into two
groups, a bilateral nephrectomy group (BNex, n = 11) and a
sham group (BNex sham, n = 6). The animals were bilaterally
nephrectomised in one surgical session, as described
previously [34]. Animals were anesthetized by ketamine
(100mg/kg, Richter Pharma AG, Wels, Austria) and xylazine
(10mg/kg, Ecuphar N.V., Oostkamp, Belgium) administered
by intraperitoneal injection. A midline incision was made in
the BNex group; the kidneys were exposed and decapsulated.
Renal pedicles were tied offwith a suture, and the kidneys were
removed. The incision was closed with an absorbable suture.
Animals in the sham group underwent sham surgery. Both
kidneys of the rats in this group were decapsulated. Animals
were sacrificed 48 hours after surgery, under general anesthe-
sia. Blood was collected into EDTA-coated blood collection
tubes (Sarstedt, Numbrecht, Germany) from the abdominal
aorta. Plasma was obtained by centrifugation (5000 g for 5
minutes) and stored at -20°C until further analysis.
2.3. Modeling of Chronic Kidney Disease. To model CKD, 5/6
nephrectomy was conducted. Rats were divided into two
groups, a 5/6 nephrectomised (5/6 Nex, n = 14) and a sham
group (5/6 Nex sham, n = 9). The animals in the 5/6 Nex
group underwent subtotal (5/6) nephrectomy in two surgical
steps, as reported previously [35]. Briefly, animals were anes-
thetized by ketamine (100mg/kg, Richter Pharma AG, Wels,
Austria) and xylazine (10mg/kg, Ecuphar N.V., Oostkamp,
Belgium) administered by intraperitoneal injection. A mid-
line incision was made on the left side, and the left kidney
was exposed. The kidney was decapsulated, and the upper
and lower kidney poles were removed. Bleeding was stopped
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by Gelaspon (Chauvin Ankerpharm GmbH, Rudolstadt,
Germany), and the incision was closed with an absorbable
suture. After the recovery period (14 days later), a similar
incision was made on the right side, the renal vessels were
ligated, and the decapsulated kidney was removed. Animals
in the 5/6 Nex sham group underwent sham surgery. The
kidneys of the rats in this group were decapsulated at the time
of the first surgery. Animals were sacrificed 6 months after
surgery under general anesthesia. Animals were placed in
metabolic cages (4 hours) for urine collection. Plasma sam-
ples were obtained in the same manner as described in the
AKI model.
2.4. Biochemical Analysis. Three hundred and fifty microli-
ters of plasma were used to measure plasma creatinine, urea,
and albuminuria concentrations using the Biolis 24i Pre-
mium automated clinical analyzer (Tokyo Boeki Medical
System Ltd., Tokyo, Japan) [36]. The principle of urea mea-
surement is based on the hydrolysis of urea by urease to form
ammonium and carbonate. The second step is based on the
reaction 2-oxoglutarate that reacts with ammonium in the
presence of glutamate dehydrogenase (GLDH) and the coen-
zyme NADH. This reaction produces L-glutamate [37]. The
measurement of creatinine is based on its reaction with picric
acid in alkaline conditions that results in a reddish complex
[38]. The plasma concentrations of kidney injury molecule
1 (KIM-1) were measured using the commercial rat KIM-1
ELISA kit (R&D Systems Inc., Abingdon, UK) according to
the manufacturer’s protocol.
2.5. Oxidative Stress and Antioxidant Status Analysis.
Markers of oxidative stress and antioxidant status were
measured in plasma samples using a Synergy H1 multimode
microplate reader (BioTek Instruments, Inc., Winooski,
VT, USA).
TBARS were measured by pipetting 20μl of samples or
standards (1,1,3,3-tetraethoxypropane), 30 μl of distilled
water, 20μl of 0.67% thiobarbituric acid, and 20μl of glacial
acetic acid in a microtiter plate. The plates were mixed and
incubated for 45 minutes at 95°C. 100μl of n-butanol was
added into the samples, and the plates were centrifuged
(2000 g/10min/4°C). Seventy microliters of the upper phase
was transferred into a new microtiter plate, and fluorescence
was measured at ex = 515 nm and λem = 535 nm. AOPP was
assessed by mixing 200 μl of samples and standards (chlo-
ramine T mixed with potassium iodide) with 20μl of gla-
cial acetic acid for 2 minutes. Absorbance was measured at
340nm. AGEs were measured by pipetting 20μl of sample
or standards (AGE-BSA) and 180μl of PBS into a dark
microtiter plate, vortexing and measuring fluorescence at
ex = 370 nm and λem = 440 nm. For fructosamine measure-
ment, 20 μl of the samples and standards (16mmol/l
1-deoxy-morpholino-D-fructose) was mixed with 100 μl
of 0.25mmol/l nitroblue tetrazolium containing 1mmol/l
nitroblue tetrazolium and 0.1mol/l sodium carbonate
buffer (pH = 10 35). Samples were incubated at 37°C for
15 minutes. Absorbance was measured at 530nm.
For TAC measurement, samples were mixed with acetate
buffer (pH = 5 8). Absorbance was measured at 660nm as
blank. When the ABTS solution (2.2′-azino-bis(3-ethyl-
benzthiazoline-6-sulphonic acid with acetate buffer)) was
added, the absorbance was measured again at 660nm. The
blank absorbance values were subtracted from the values
obtained by the second measurement. For FRAP assessment,
200 μl of warmed (37°C) FRAP reagent (containing acetate
buffer (pH = 3 6), tripyridyl-s-triazine, FeCl3∗6H2O, and
water) was pipetted into a microtiter plate, and absorbance
was measured as blank. Afterwards, 20 μl of samples and
standards (100mmol/l FeSO4∗7H2O) was added. Absor-
bance was measured again at 530nm. The blank absorbance
values were subtracted from the values obtained by the sec-
ond measurement [39].
For the measurement of proteins, 10μl of the samples
and standards (bovine serum albumin) was mixed with
200μl of the working solution (bicinchoninic acid and
copper sulphate, 49 : 1 ratio, respectively). The plate was
incubated at 37°C for 30 minutes. After cooling, absor-
bance was measured at 562 nm. All markers measured in
plasma were normalized to plasma protein concentrations.
Markers measured in urine were normalized to urinary
creatinine concentrations.
2.6. Statistical Analysis. GraphPad Prism 5.0 (GraphPad
Software, San Diego, CA, USA) was used for the statis-
tical analyses. After testing for normality with the
D’Agostino-Pearson omnibus test, data were analyzed
with the Mann–Whitney U test. The Spearman correla-
tion test and linear regression were used to evaluate
the linear associations between quantitative variables. A
value of p < 0 05 was considered statistically significant.
3. Results
Concentrations of creatinine in the plasma of the BNex
group were 20-fold higher when compared to the BNex sham
group (Figure 1(a); U = 0, p < 0 001). Blood urea in the BNex
group was significantly higher when compared to the BNex
sham group by 484% (Figure 1(b); U = 0, p < 0 001). Plasma
creatinine concentrations in the 5/6 Nex group were signifi-
cantly higher than in the 5/6 Nex sham group by 48%
(Figure 1(c); U = 18, p < 0 01). Blood urea was 2-fold higher
in the 5/6 Nex group than in the 5/6 Nex sham group
(Figure 1(d); U = 10, p < 0 001). One animal in the BNex
group did not show elevated levels of plasma creatinine
(37.56μmol/l), nor urea (11.70mmol/l), which would com-
ply with the modeling of AKI and was thus removed from
further analyses.
There were no differences between the BNex and the
BNex sham groups in TBARS concentrations (Figure 2(a)).
In plasma TBARS, no significant differences were found
between the 5/6 Nex and the 5/6 Nex sham groups either
(Figure 3(a)). Plasma AOPP concentrations were 2-fold
higher in the BNex group, when compared to the BNex sham
group (Figure 2(b); U = 9, p < 0 05). In plasma AOPP, a
significant difference was found between the 5/6 Nex and
the 5/6 Nex sham groups, the first being higher by 102%
(Figure 3(b); U = 28, p < 0 05).
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AGE concentrations were 2-fold higher in the plasma of
the BNex group, when compared to the BNex sham group
(Figure 2(c); U = 0, p < 0 01). No significant differences were
found in plasma AGE concentration between the 5/6 Nex
and the 5/6 Nex sham groups (Figure 3(c)). Fructosamine
concentrations differed significantly between the BNex and
the BNex sham group as well, the BNex group being higher
by 54% (Figure 2(d); U = 4, p < 0 01). In plasma fructosa-
mine, a significant difference was found between the 5/6
Nex and the 5/6 Nex sham groups. The 5/6 Nex group had
3-fold higher fructosamine concentrations (Figure 3(d);
U = 10, p < 0 01). Between the BNex and the BNex sham
groups, there was a significant difference in TAC, the
BNex being 2-fold higher (Figure 2(e); U = 5, p < 0 05).
TAC concentrations in plasma did not differ between
the 5/6 Nex and the 5/6 Nex sham groups (Figure 3(e)).
There were no differences between the BNex and the BNex
sham groups in FRAP concentrations (Figure 2(f)). In
plasma FRAP, a significant difference was found between
the 5/6 Nex and the 5/6 Nex sham groups, the first being
2-fold higher (Figure 3(f); U = 22, p < 0 05).
Additionally, to the plasma concentrations, TBARS,
AOPP, fructosamine, and FRAP were all measurable in the
urine of 5/6 Nex rats. Of these, AOPP differed most signifi-
cantly from the sham group. AOPP in 5/6 Nex were 2-fold
higher in urine when compared to 5/6 Nex sham group
(Figure 4(b); U = 7, p < 0 001). TBARS, fructosamine, and
FRAP in urine were increased in the 5/6 Nex group by
approximately 50% (Figures 4(a), 4(c), and 4(d); U = 40, 34,
and 32, respectively, p < 0 05 for all three markers) when
compared to the control group.
In 5/6 Nex as a model of CKD, urinary AOPP signifi-
cantly and positively correlated with urinary KIM-1
(r = 0 70; p < 0 05). Also, urinary fructosamine and FRAP
significantly correlated with ACR (r = 0 72 and r = 0 82;
p < 0 05, respectively) and albuminuria (r = 0 62 and r =
0 82; p < 0 05, respectively), but neither with plasma nor
with urinary KIM-1 (Table 1).
4. Discussion
The results of this experiment confirmed the association
between elevated systemic oxidative stress and acute and
chronic renal failure. Although proteins are relatively resis-
tant to damage by prooxidants, AOPP concentrations were
2-fold higher in rats with both acute and chronic renal failure
compared to their sham-operated counterparts. A 2-fold
increase in AOPP was present not only in plasma but also
in the urine of CKD rats. These findings are in line with
previous studies in AKI and CKD patients [40, 41]. It
has been proposed that AOPP not only are associated with

































































Figure 1: Renal function parameters in rats with acute and chronic kidney injury and sham-operated rats. (a) Plasma creatinine in bilaterally
nephrectomised (BNex) and sham (BNex sham) rats, (b) plasma urea in BNex and BNex sham rats, (c) plasma creatinine in 5/6
nephrectomised (5/6 Nex) and sham (5/6 Nex sham) rats, and (d) plasma urea in 5/6 Nex and 5/6 Nex sham rats. ∗∗p < 0 01, ∗∗∗p < 0 001.
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through cellular and molecular mechanisms. These mech-
anisms include triggering a cascade of signaling events that
lead to superoxide generation, NF-κB activation, the over-
production of extracellular matrix, apoptosis of podocytes,
endothelial inflammation, and monocyte activation [42, 43].
Moreover, elevated AOPP were found to be associated with
poor prognosis of patients with IgA nephropathy [44]. On
the other hand, during CKD, the excessive glomerular
protein leakage might contribute to the absolute numbers
of AOPP.
This study found no differences between 5/6 Nex or
BNex animals and the sham groups in oxidized lipid
concentrations measured by TBARS in plasma, contrary to
other studies. A previous study showed that products of lipid
peroxidation could be increasing in AKI in a time-dependent
manner. It could be argued that these damaged lipids would
have increased should the experiment lasted longer,
although, in the mentioned studies, lipid peroxidation prod-
ucts were already significantly higher after 48 hours in rats
with AKI [45, 46]. On the other hand, urinary TBARS were
higher in CKD rats, suggesting their clearance from circula-
tion despite reduced renal function. Unfortunately, due to
the anuria of the BNex rats, we were unable to determine





























































































Figure 2: Oxidative stress and antioxidant status markers in the plasma of bilaterally nephrectomised (BNex) and sham (BNex sham) rats. (a)
TBARS: thiobarbituric acid reactive substances, (b) AOPP: advanced oxidation protein products, (c) AGEs: advanced glycation end products,
(d) fructosamine, (e) TAC: total antioxidant capacity, and (f) FRAP: ferric reducing antioxidant power. ∗p < 0 05, ∗∗p < 0 01.
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Products of carbonyl stress, such as fructosamine and
AGEs, are produced during aging and accumulate in circula-
tion and tissues. Kidneys play an important part in their dis-
posal, and fructosamine and AGEs have been shown to be
elevated when kidney function is compromised [47, 48].
The results of this experiment showed that the concentration
of fructosamine was higher in AKI and CKD, but AGEs were
higher only in the AKI model. This could indicate that the
remaining kidney function in the mild 5/6 Nex model of
CKD was sufficient to filter AGEs from circulation. The rea-
sons of the accumulation of AGEs during uremia are not fully
understood. Increased concentration of circulating AGEs in
patients with kidney diseases may result from an increased
production due to uremia-related consequences or decreased
renal disposal [49]. According to previous results, low molec-
ular weight AGEs are easily removed from the body by renal
clearance [50]. Thus, it seems that a partial maintenance of
low molecular weight AGE disposal by the damaged kidneys
prevented the elevation of plasma AGE concentrations in 5/6
Nex. However, it has also been shown that one fraction of
plasma AGEs is linked to binding proteins, mainly albumin
in uremic patients. Glomerular filtration or dialysis does
not remove these proteins. Thus, accumulation of higher
molecular weight AGEs could not be explained by decreased





























































































Figure 3: Oxidative stress and antioxidant status markers in the plasma of 5/6 nephrectomised (5/6 Nex) and sham (5/6 Nex sham) rats. (a)
TBARS: thiobarbituric acid reactive substances, (b) AOPP: advanced oxidation protein products, (c) AGEs: advanced glycation end products,
(d) fructosamine, (e) TAC: total antioxidant capacity, and (f) FRAP: ferric reducing antioxidant power. ∗p < 0 05, ∗∗p < 0 01.
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renal clearance [51]. In addition, the elevated urinary levels
of fructosamine in 5/6 Nex rats confirm their clearance via
the kidneys.
The results also showed that the concentrations of anti-
oxidant status markers were higher in the 5/6 Nex and BNex
groups than in controls—more precisely, FRAP was higher in
























































































Figure 4: Oxidative stress and antioxidant status markers in the urine of 5/6 nephrectomised (5/6 Nex) and sham (5/6 Nex sham) rats. (a)
TBARS: thiobarbituric acid reactive substances, (b) AOPP: advanced oxidation protein products, (c) fructosamine, and (d) FRAP: ferric
reducing antioxidant power. ∗p < 0 05, ∗∗∗p < 0 001.
Table 1: Correlation coefficients (Spearman) between plasma markers, thiobarbituric acid reactive substances (TBARS), advanced oxidation
protein products (AOPP), advanced glycation end products (AGEs), fructosamine, total antioxidant capacity (TAC), and ferric reducing
antioxidant power (FRAP), and urinary markers, TBARS, AOPP, fructosamine, FRAP, plasma creatinine, blood urea nitrogen (BUN),
urinary kidney injury molecule-1 (uKIM-1), plasma kidney injury molecule-1 (pKIM-1), albumin/creatinine ratio of urine (ACR), and













Plasma markers of OS
TBARS (μmol/g) -0.42 n.s. -0.38 n.s. 0.06 n.s. -0.30 n.s. 0.33 n.s. 0.39 n.s.
AOPP (μmol/g) -0.12 n.s. 0.05 n.s -0.15 n.s. -0.05 n.s. -0.07 n.s. -0.08 n.s.
AGEs (g/g) -0.60∗ -0.38 n.s. -0.38 n.s. -0.62∗ -0.32 n.s -0.11 n.s.
Fructosamine (mmol/g) 0.10 n.s. 0.17 n.s. -0.43 n.s. -0.05 n.s. -0.06 n.s. 0.07 n.s.
TAC (μmol/g) 0.01 n.s. 0.10 n.s. 0.28 n.s. 0.17 n.s. 0.0 n.s. -0.08 n.s.
FRAP (μmol/g) 0.07 n.s. 0.10 n.s. 0.06 n.s. 0.12 n.s. 0.14 n.s. 0.12 n.s.
Urinary markers of OS
TBARS (μmol/mmol) 0.23 n.s. 0.44 n.s. -0.06 n.s. 0.26 n.s. 0.30 n.s. 0.01 n.s.
AOPP (μmol/mmol∗g) 0.23 n.s. 0.06 n.s. 0.38 n.s. 0.70∗ 0.51 n.s. -0.10 n.s.
Fructosamine
(mmol/mmol)
-0.31 n.s. -0.32 n.s. 0.13 n.s. 0.17 n.s. 0.72∗ 0.62∗
FRAP (μmol/mmol) -0.33 n.s. -0.28 n.s. 0.49 n.s. 0.32 n.s. 0.82∗∗ 0.69∗
∗p < 0 05, ∗∗p < 0 01.
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the 5/6 Nex group, and TAC was found to be elevated in the
BNex group when compared to sham animals. These results
are in line with a different study showing higher TAC in a rat
model of AKI than in sham-operated animals [52]. Another
study involving CKD patients has shown higher FRAP
concentrations in patients than in controls [53]. In addition,
urinary FRAP levels were also elevated in 5/6 Nex, confirm-
ing the situation observed in plasma. Although we cannot
fully explain the difference between AKI and CKD, this could
be potentially used as a differentiating marker between AKI
and CKD. It is assumed that the antioxidant activity rose as
an answer to present systemic oxidative stress in both disease
states. Paradoxically, the antioxidant status may increase in
renal disease because of the accumulation of uremic toxins
with scavenging capacity, such as indole derivatives and hip-
purate [48, 52]. In addition, the difference might be the result
of the differences of the measured substances between the
two methods. While TAC includes the SH/thiol groups pres-
ent in proteins and reduced glutathione, these are not
detected by the FRAP method. Due to the complete anuria
in the BNex rats compared to the known proteinuria in the
5/6 Nex model, the higher TAC in BNex might be attributed
to a higher amount of small molecular weight proteins in the
plasma of BNex rats [54].
To further address the applicability of the oxidative stress
markers in renal disease, we correlated them with the
standard plasmatic and urinary markers of renal function
and injury.
In CKD, we found a negative correlation between plasma
AGEs vs. plasma creatinine and uKIM-1. Whether this
observation is of any prognostic or diagnostic value is cur-
rently unknown. In the urine, there was a positive correlation
between AOPP and uKIM-1, suggesting that urinary AOPP
might closely reflect proximal tubular injury. On the other
hand, urinary fructosamine and FRAP correlated with ACR
and albuminuria, but not with uKIM-1, suggesting that they
might more closely reflect glomerular injury. However,
further studies are needed to prove these assumptions.
The limitation of this study is that the urinary concen-
tration of oxidative stress and antioxidant status markers
could not be assessed in BNex rats, due to anuria which
is typical for this model [55]. Further studies will be aimed
at the models with residual kidney function, which are not
completely anuric.
In conclusion, this study confirms the association of AKI
and CKD with elevated systemic oxidative stress markers.
Furthermore, to our knowledge, this study is the first to
describe this particular set of oxidative stress and antioxidant
status markers measured parallel in AKI and CKD. It shows
that oxidative damage to proteins is apparent in both disease
states in plasma and in urine. Nevertheless, we do not report
elevated lipid peroxidation in kidney disease in plasma, nei-
ther in AKI nor in CKD. Interestingly, in the urine, we found
elevated markers of lipid peroxidation in CKD, which might
suggest urine as a superior fluid for the determination of lipid
peroxidation in CKD. Carbonyl stress is apparent by an
increase in fructosamine in both disease states, but the rem-
nant kidney function in CKD appears to be sufficient to
excrete AGEs of lower molecular weight. Antioxidant status
can also increase in AKI and CKD, likely due to an increase
in uremic toxins with antioxidant capacity. However differ-
ent antioxidant systems probably take part in increased
oxidative stress during CKD and AKI. Future studies
should be focused on AOPP and fructosamine as potential
biomarkers, and data on their dynamics and urinary con-
centrations in AKI should be gathered. Further clarifica-
tion of different antioxidant mechanisms during AKI and
CKD is needed.
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